Last updated: 2026-09-05 20:03:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Ocugen, Inc. (OCGN) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $1.36, with a market capitalization of $447.63M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.01 to $2.73. This page covers its latest market performance, valuation, price trends and company information.
$447.63M | |
$1.32 | |
$18.77 | |
$0.17 | |
$1.35 | |
3.37M | |
-- | |
-- | |
$2.73 | |
$1.01 | |
-- | |
-- |
Ocugen, Inc. (OCGN) last closed at $1.35 as of 2026-09-04 23:57:00, unchanged from the previous close of $1.35.
During the latest regular trading session, OCGN traded between $0.17 and $18.77, with a volume of 3.37M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Ocugen, Inc. (OCGN) moved from $1.32 to $1.36, representing a gain of 3.19% ($0.04).
The stock traded between $1.32 and $1.38 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 3.30 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 20.2%
OCGN is currently trading at $1.36, placing it 20.2% of the way from its 52-week low of $1.01 to its 52-week high of $2.73. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 116 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Ocugen, Inc. (OCGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.